Does the failure to provide equitable access to treatment lead to action by NHS organisations: the case of biologics for South Asians with inflammatory bowel disease?
Aims: The purpose of this study was to identify whether NHS Trusts where discrimination in the delivery of care to patients from the South Asian community had been demonstrated had taken any actions to address the issue over the subsequent year.Methods: Freedom of information requests were sent to...
Gespeichert in:
Veröffentlicht in: | Denning law journal 2020-01, Vol.31 (1) |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | |
container_title | Denning law journal |
container_volume | 31 |
creator | Mayberry, John Francis |
description | Aims: The purpose of this study was to identify whether NHS Trusts where discrimination in the delivery of care to patients from the South Asian community had been demonstrated had taken any actions to address the issue over the subsequent year.Methods: Freedom of information requests were sent to three trusts which had provided evidence of disparate provision of biologic therapy to patients with Crohn’s disease, their associated Clinical Commissioning Groups and Healthwatch organisations to seek evidence they had remedied the situation. Requests were also sent to the Care Quality Commission, NHS Improvement and the Equality and Human Rights Commission seeking examples where they had responded to inequitable delivery of care related to ethnicity.Results: No organisation had any evidence of responses to the situation, many unable to accept its existence.Conclusion: Legal duties are discussed and the only remedy appears to be through the tort of negligence. |
doi_str_mv | 10.5750/dlj.v31i1.1751 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2659628961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2659628961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c671-c0c7c979b5bf4af0612188b8589fc74dbb42b0f4990a087a96e0c0708f2c878a3</originalsourceid><addsrcrecordid>eNotkU9P3DAQxa2qlbqlXDmP1HMW25v4Ty8Voi1UQu0B7tHYGYNX2RhsB7RfqJ-zCfQ0ozdv3kjzY-xM8G2nO34-jPvt805EsRW6E-_YRvJWN1Kr7j3bcKlsI6yUH9mnUvact0oruWF_vycqUB8IAsZxzgQ1wWNOz3EgoKc5VnQjAXpPpayzmgnrgaYKI-GwKuhrTBO4I_y-voWU73GKBVetfH1N9lgIUgAX05juoy8QUobbNNcHuCgRpwIvcenjFEY8HLCmfASXXmiEIRZatr99Zh8CjoVO_9cTdvfzx93ldXPz5-rX5cVN45UWjedee6ut61xoMXAlpDDGmc7Y4HU7ONdKx0NrLUduNFpF3HPNTZDeaIO7E_blLXb5wNNMpfb7NOdpudhL1VkljVVicW3fXD6nUjKF_jHHA-ZjL3i_ougXFP0rin5FsfsH3duAEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2659628961</pqid></control><display><type>article</type><title>Does the failure to provide equitable access to treatment lead to action by NHS organisations: the case of biologics for South Asians with inflammatory bowel disease?</title><source>DOAJ Directory of Open Access Journals</source><source>HeinOnline Law Journal Library</source><creator>Mayberry, John Francis</creator><creatorcontrib>Mayberry, John Francis</creatorcontrib><description>Aims: The purpose of this study was to identify whether NHS Trusts where discrimination in the delivery of care to patients from the South Asian community had been demonstrated had taken any actions to address the issue over the subsequent year.Methods: Freedom of information requests were sent to three trusts which had provided evidence of disparate provision of biologic therapy to patients with Crohn’s disease, their associated Clinical Commissioning Groups and Healthwatch organisations to seek evidence they had remedied the situation. Requests were also sent to the Care Quality Commission, NHS Improvement and the Equality and Human Rights Commission seeking examples where they had responded to inequitable delivery of care related to ethnicity.Results: No organisation had any evidence of responses to the situation, many unable to accept its existence.Conclusion: Legal duties are discussed and the only remedy appears to be through the tort of negligence.</description><identifier>ISSN: 0269-1922</identifier><identifier>EISSN: 2047-2765</identifier><identifier>DOI: 10.5750/dlj.v31i1.1751</identifier><language>eng</language><publisher>Buckingham: The University of Buckingham Press</publisher><subject>Asian people ; Biological products ; Cancer therapies ; Crohn's disease ; Ethnicity ; Gastroenterology ; Hospitals ; Human rights ; Inflammatory bowel disease</subject><ispartof>Denning law journal, 2020-01, Vol.31 (1)</ispartof><rights>2020. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Mayberry, John Francis</creatorcontrib><title>Does the failure to provide equitable access to treatment lead to action by NHS organisations: the case of biologics for South Asians with inflammatory bowel disease?</title><title>Denning law journal</title><description>Aims: The purpose of this study was to identify whether NHS Trusts where discrimination in the delivery of care to patients from the South Asian community had been demonstrated had taken any actions to address the issue over the subsequent year.Methods: Freedom of information requests were sent to three trusts which had provided evidence of disparate provision of biologic therapy to patients with Crohn’s disease, their associated Clinical Commissioning Groups and Healthwatch organisations to seek evidence they had remedied the situation. Requests were also sent to the Care Quality Commission, NHS Improvement and the Equality and Human Rights Commission seeking examples where they had responded to inequitable delivery of care related to ethnicity.Results: No organisation had any evidence of responses to the situation, many unable to accept its existence.Conclusion: Legal duties are discussed and the only remedy appears to be through the tort of negligence.</description><subject>Asian people</subject><subject>Biological products</subject><subject>Cancer therapies</subject><subject>Crohn's disease</subject><subject>Ethnicity</subject><subject>Gastroenterology</subject><subject>Hospitals</subject><subject>Human rights</subject><subject>Inflammatory bowel disease</subject><issn>0269-1922</issn><issn>2047-2765</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNotkU9P3DAQxa2qlbqlXDmP1HMW25v4Ty8Voi1UQu0B7tHYGYNX2RhsB7RfqJ-zCfQ0ozdv3kjzY-xM8G2nO34-jPvt805EsRW6E-_YRvJWN1Kr7j3bcKlsI6yUH9mnUvact0oruWF_vycqUB8IAsZxzgQ1wWNOz3EgoKc5VnQjAXpPpayzmgnrgaYKI-GwKuhrTBO4I_y-voWU73GKBVetfH1N9lgIUgAX05juoy8QUobbNNcHuCgRpwIvcenjFEY8HLCmfASXXmiEIRZatr99Zh8CjoVO_9cTdvfzx93ldXPz5-rX5cVN45UWjedee6ut61xoMXAlpDDGmc7Y4HU7ONdKx0NrLUduNFpF3HPNTZDeaIO7E_blLXb5wNNMpfb7NOdpudhL1VkljVVicW3fXD6nUjKF_jHHA-ZjL3i_ougXFP0rin5FsfsH3duAEg</recordid><startdate>20200108</startdate><enddate>20200108</enddate><creator>Mayberry, John Francis</creator><general>The University of Buckingham Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7WY</scope><scope>7WZ</scope><scope>7XB</scope><scope>87Z</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>F~G</scope><scope>K60</scope><scope>K6~</scope><scope>L.-</scope><scope>M0C</scope><scope>PIMPY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20200108</creationdate><title>Does the failure to provide equitable access to treatment lead to action by NHS organisations: the case of biologics for South Asians with inflammatory bowel disease?</title><author>Mayberry, John Francis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c671-c0c7c979b5bf4af0612188b8589fc74dbb42b0f4990a087a96e0c0708f2c878a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Asian people</topic><topic>Biological products</topic><topic>Cancer therapies</topic><topic>Crohn's disease</topic><topic>Ethnicity</topic><topic>Gastroenterology</topic><topic>Hospitals</topic><topic>Human rights</topic><topic>Inflammatory bowel disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mayberry, John Francis</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Access via ABI/INFORM (ProQuest)</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Global</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Denning law journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mayberry, John Francis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does the failure to provide equitable access to treatment lead to action by NHS organisations: the case of biologics for South Asians with inflammatory bowel disease?</atitle><jtitle>Denning law journal</jtitle><date>2020-01-08</date><risdate>2020</risdate><volume>31</volume><issue>1</issue><issn>0269-1922</issn><eissn>2047-2765</eissn><abstract>Aims: The purpose of this study was to identify whether NHS Trusts where discrimination in the delivery of care to patients from the South Asian community had been demonstrated had taken any actions to address the issue over the subsequent year.Methods: Freedom of information requests were sent to three trusts which had provided evidence of disparate provision of biologic therapy to patients with Crohn’s disease, their associated Clinical Commissioning Groups and Healthwatch organisations to seek evidence they had remedied the situation. Requests were also sent to the Care Quality Commission, NHS Improvement and the Equality and Human Rights Commission seeking examples where they had responded to inequitable delivery of care related to ethnicity.Results: No organisation had any evidence of responses to the situation, many unable to accept its existence.Conclusion: Legal duties are discussed and the only remedy appears to be through the tort of negligence.</abstract><cop>Buckingham</cop><pub>The University of Buckingham Press</pub><doi>10.5750/dlj.v31i1.1751</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-1922 |
ispartof | Denning law journal, 2020-01, Vol.31 (1) |
issn | 0269-1922 2047-2765 |
language | eng |
recordid | cdi_proquest_journals_2659628961 |
source | DOAJ Directory of Open Access Journals; HeinOnline Law Journal Library |
subjects | Asian people Biological products Cancer therapies Crohn's disease Ethnicity Gastroenterology Hospitals Human rights Inflammatory bowel disease |
title | Does the failure to provide equitable access to treatment lead to action by NHS organisations: the case of biologics for South Asians with inflammatory bowel disease? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T01%3A54%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20the%20failure%20to%20provide%20equitable%20access%20to%20treatment%20lead%20to%20action%20by%20NHS%20organisations:%20the%20case%20of%20biologics%20for%20South%20Asians%20with%20inflammatory%20bowel%20disease?&rft.jtitle=Denning%20law%20journal&rft.au=Mayberry,%20John%20Francis&rft.date=2020-01-08&rft.volume=31&rft.issue=1&rft.issn=0269-1922&rft.eissn=2047-2765&rft_id=info:doi/10.5750/dlj.v31i1.1751&rft_dat=%3Cproquest_cross%3E2659628961%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2659628961&rft_id=info:pmid/&rfr_iscdi=true |